Sartorius Life Sciences Group launches an integrated system for the production and quality control (QC) of autologous cell therapies. Eveo’s modular cell therapy platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative therapies such as CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally new approach to cell therapy production that strengthens the company’s position in the dynamic market for advanced therapies.
Cell therapies are redefining medical possibilities. However, they remain accessible to only a small proportion of patients because the construction is complex, capacity limited and therefore expensive. With our integrated platform, we tackle these structural bottlenecks head-on. By combining raw materials, production equipment, software and QC testing into a scalable system, we enable our customers to expand production, significantly reduce cost per dose and shorten vein-to-vein time for patients.
René Fáber, Member of the Executive Board, Sartorius
Conventional production models for autologous cell therapies rely on centralized, purpose-built facilities, requiring significant greenfield investment, staff recruitment, training and multi-year build-out phases. However, approximately 60 percent of regulatory disruptions in cell therapy manufacturing are caused by manufacturing and process-related issues.
The new Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, washing and concentration, and final synthesis in a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies. The system’s compact design supports implementation in existing facilities with existing staff, enables operation in lower-end environments, and supports centralized and decentralized production models.
Sartorius has partnered with ElevateBio, a leading cell therapy CDMO, among other partners, to test the Eveo platform. In a successful pilot, the system performed according to design expectations, proving its real-world applicability. Because of its multi-parallel configuration, an operator can process eight batches of patients simultaneously in the same cleanroom space traditionally required for two batches. Assuming a manufacturing time of about seven days per batch and 50 weeks of production per year, Eveo enables the production of more than 350 doses per year in a footprint that currently yields about 100 doses – a nearly fourfold increase. Financial modeling confirms that the platform can reduce construction costs by around 90 percent.
Quality control also represents a major hurdle in cell therapy production and delivery. With Sartorius’ capabilities in live cell imaging and high-throughput flow cytometry included in the Eveo platform, the technology addresses key analytical challenges and enables accessibility.
Sartorius plans to begin accepting orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its customer manufacturers.
